Company Filing History:

37 out of 1,168

Glaxo Group Limited

Years Active: 1981-2001

Loading Chart...

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6228853 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase (2001-05-08),

2. 6215002 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase (2001-04-10),

3. 6177425 - Pyrrolopyrrolone derivatives (2001-01-23),

4. 6057457 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase (2000-05-02),

5. 5994344 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase (1999-11-30),

6. 5646140 - 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic (1997-07-08),

7. 5641775 - 3-phenylureido-1,5-benzodiazepine-diones useful as gastrin or antagonists (1997-06-24),

8. 5637697 - 1,5-benzodiazepine derivatives and their use in medicine (1997-06-10),

9. 5585376 - 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic (1996-12-17),

10. 5580895 - 1,5-benzodiazepine derivatives (1996-12-03),

11. 5283262 - Phenethanolamine derivatives (1994-02-01),

12. 5243076 - Phenethanolamine derivatives (1993-09-07),

13. 5225445 - Phenethanolamine derivatives having .beta..sub.2 -adrenoreceptor (1993-07-06),

14. 5221695 - Aqueous formulation containing a piperidinylcyclopentylheptenoic acid (1993-06-22),

15. 5126375 - Phenethanolamine derivatives (1992-06-30),

Title: Harry Finch: Innovator in Pharmaceutical Patents

Introduction

Harry Finch, a prolific inventor based in Letchworth, Great Britain, holds an impressive portfolio of 47 patents. His innovative work primarily focuses on developing compounds that address critical health issues, particularly in the realm of respiratory diseases.

Latest Patents

Among his latest contributions to the field are patents related to Pyrrolopyrrolone derivatives. These formulations are designed as inhibitors of neutrophil elastase, a significant factor in inflammatory diseases of the respiratory tract. The compounds of formula (I) provided in his patents demonstrate the potential for substantial therapeutic applications. Additionally, he has described processes for making compounds of formula (XXVIII), further elucidating the scientific foundations of his inventions.

Career Highlights

Harry Finch has made significant strides during his career while collaborating with major pharmaceutical entities. He has worked with Glaxo Group Limited and Glaxo Wellcome Inc., where he has contributed to advancing medical knowledge and treatment methodologies.

Collaborations

In his journey of innovation, Finch has collaborated with notable coworkers, including Lawrence H. Lunts and Alan Naylor. Their collective expertise has undoubtedly enriched the research and development of Davis Finch's groundbreaking inventions.

Conclusion

Harry Finch continues to be a significant player in the field of pharmaceutical research and patent creation. His work in developing inhibitors for neutrophil elastase exemplifies his commitment to addressing crucial health challenges and showcases the profound impact of his inventive spirit on the medical community.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.